McCormick Place Chicago, IL, USA

Transcription

HLR42220_ASCO_PocketPlanner
21/5/07
18:22
Day-by-day guide to ASCO
1-5 June 2007
McCormick Place
Chicago, IL, USA
Page 1
21/5/07
18:22
Page 4
21/5/07
18:22
Page 1
Contents
Congress details
2
Dining
3
Safety
4
Congress site plan
6
Key
11
Saturday 2 June
12
Sunday 3 June
19
Monday 4 June
24
Tuesday 5 June
28
Hotels
30
Map
31
21/5/07
18:22
Congress details
Congress venue
McCormick Place
2301 South Lake Shore Drive
Chicago, IL 60616, USA
Tel: 312 791 7000; Fax: 312 791 6543
Congress registration
Location: McCormick Place
Friday 1 June:
Onsite registration opens
(including self-registration)
Tuesday 5 June:
Onsite registration closes
Congress dates and opening hours
Friday 1 June
Saturday 2 June
Sunday 3 June
Monday 4 June
Tuesday 5 June
2
13:00-18:00
07:30-18:00
07:30-18:00
07:30-18:00
07:30-12:45
Page 2
21/5/07
18:22
Page 3
Dining
Recommended restaurants
Aria (American Contemporary with International Flair)
200 North Columbus Drive, Chicago, IL 60601
Tel: 312 444 9494
Bandera (American Contemporary)
535 North Michigan Avenue, Chicago, IL 60611
Tel: 312 644 3524
Catch 35 (Seafood)
35 West Wacker Drive, Chicago, IL 60601
Tel: 312 346 3500
China Grill (Pan-Asian)
230 North Michigan Avenue, Chicago, IL 60601
Tel: 312 334 6700
Kevin (French Fusion)
9 West Hubbard Street, Chicago, IL 60610
Tel: 312 595 0055
McCormick & Schmick’s (Seafood)
1 East Wacker Drive, Chicago, IL 60601
Tel: 312 923 7226
Morton’s (Steak and Seafood)
65 East Wacker Place, Chicago, IL 60601
Tel: 312 201 0410
Phil Stefani’s 437 Rush (Italian Steakhouse)
437 North Rush Street, Chicago, IL 60611
Tel: 312 222 0101
Shula’s Steakhouse (Steak and Seafood)
301 East North Water Street, Chicago, IL 60611
Tel: 312 670 0788
The Palm (Steak, Seafood and Italian)
323 East Wacker Drive, Chicago IL 60601
Tel: 312 616 1000
Vermilion (Indian/Latin Fusion)
10 West Hubbard Street, Chicago, IL 60610
Tel: 312 527 4060
Volare (Italian)
201 East Grand Avenue, Chicago, IL 60611
Tel: 312 410 9900
3
21/5/07
18:22
Page 4
Safety
Safety tips
On leaving the congress site you are advised to remove your
ASCO name badge or any Roche identity insignia
Keep jewellery or accessories to a minimum and do not display
cameras or bags that can draw attention
Keep your wallet or precious belongings in your inside front pocket or
wear your handbag across your shoulders
Sightsee on well-lit, well-travelled streets and passages either with a
colleague or in a group
Important telephone numbers
Emergency services (Police, Ambulance, Fire): 911
Non-emergency services (Police and City Services): 311
Yellow Cab Chicago: 312 8294 222
Chicago Office of Tourism: 312 744 2400
4
21/5/07
18:22
Page 5
5
21/5/07
18:22
Page 6
Congress site plan
6
21/5/07
18:22
Page 7
7
21/5/07
18:22
Page 8
Floor plans
Level 4
Meeting Rooms (E450– E451)
Level 3
Exhibition Halls
Meeting Rooms (E350–E354)
Arie Crown Balcony
Level 2
Exhibition Halls
Meeting Rooms (E250–E272)
Arie Crown Theater
Arie Crown Theater
Level 1
Offices
Lakeside Center
Level 4
Meeting Rooms (N426– N427)
Level 3
Exhibition Halls
Level 2
Meeting Rooms (N226–N231)
Level 1
Exhibition Halls
Meeting Rooms (N126–N140)
North Building
8
21/5/07
18:22
Page 9
Level 5
Meeting Rooms (S501– S505)
Level 4
Vista Room (S406)
Level 3
Exhibition Halls
Grand Concourse
Level 2
Food Court/Restaurant
Shops & Services
Metra Trains
Level 1
Grand Ballroom (S100)
South Building
Level 5
Rooftop Garden
Level 4
Meeting Rooms
Level 3
Ballroom
Exhibition Hall
Level 2
Food Court/
Restaurant
Shops & Services
Level 1
Central Transportation Center
Meeting Rooms
West Building
9
10
21/5/07
18:22
Page 10
21/5/07
18:22
Page 11
Key
Key to symbols used throughout the planner
A Avastin
B Bondronat
H Herceptin
M MabThera
T Tarceva
X Xeloda
11
21/5/07
18:22
Page 12
Saturday
2 June
POSTER DICUSSION SESSION
Time: 08:00-12:00 [discussion 12:00-13:00]
Venue: S403 [S406 Vista Room]
Breast cancer - metastatic
HER2 gene amplification (HER2) and hormone receptor
expression (ER/PR) in early (EBC) and metastatic breast
cancer (MBC) in the same patients (U Wilking; Poster 10,
Abstract 1023)
X
X
X
A quality-adjusted time without symptoms or toxicity
(Q-TWiST) analysis comparing lapatinib plus capecitabine
compared to capecitabine for metastatic breast cancer
(MBC) (B Sherrill; Poster 13, Abstract 1026)
A randomized trial of capecitabine (C) given intermittently
(IC) rather than continuously (CC) compared to classical
CMF as first-line chemotherapy for advanced breast cancer
(ABC) (M Stockler; Poster 18, Abstract 1031)
Lapatinib (L) plus capecitabine (C) in HER2+ advanced
breast cancer (ABC): Genomic and updated efficacy data
(CE Geyer; Poster 22, Abstract 1035)
GENERAL POSTER SESSION
Time: 08:00-12:00
Venue: S Hall A2
Health services research
M
Cost-effectiveness of rituximab plus CVP for first-line
treatment of advanced indolent lymphoma (J Hornberger;
Poster D13, Abstract 6583)
The utilization of new oncology drugs: A global perspective
(B Jönsson; Poster F14, Abstract 6612)
M
12
Cost-effectiveness (CE) analysis of CHOP and rituximab for
diffuse large B-cell lymphoma (DLBCL) in British Columbia
(BC) (GW Loh; Poster G11, Abstract 6623)
X
Xeloda
M MabThera
21/5/07
18:22
Page 13
Saturday
2 June
Time: 08:00-12:00
Venue: S Hall A2
Lymphoma and plasma cell disorders
M
M
M
Rituximab maintenance therapy (RM) for
relapsed/refractory follicular lymphoma (FL): Long-term
economic impact in the French setting (P Brice; Poster X5,
Abstract 8076)
A phase IB safety and pharmacokinetic (PK) study of
recombinant human Apo2L/TRAIL in combination with
rituximab in patients with low-grade non-Hodgkin
lymphoma (L Yee; Poster X7, Abstract 8078)
Cost-effectiveness of rituximab maintenance therapy for
patients with follicular lymphoma: The Spanish perspective
(J Gómez Codina; Poster Z7, Abstract 8092)
ORAL ABSTRACT PRESENTATION SESSION
Time: 13:00-16:00
Venue: E Arie Crown Theater
Leukemia, myelodysplasia and transplantation
M
Seventy percent of complete responders remain in
continuous remission: Five-year follow-up of 300 patients
treated with fludarabine, cyclophosphamide, and rituximab
(FCR) as initial therapy of CLL (CS Tam; Abstract 7008)
Time: 14:15-14:30
M
Salvage therapy following failure or relapse after FCR
chemo-immunotherapy as initial treatment for chronic
lymphocytic leukemia (CLL) (MJ Keating; Abstract 7009)
Time: 14:30-14:45
M MabThera
13
21/5/07
18:22
Page 14
Saturday
2 June
Time: 13:00-16:00
Venue: N Hall B1
Lung cancer I
A
Randomised, double-blind multicentre phase III study of
bevacizumab in combination with cisplatin and gemcitabine
in chemotherapy-naïve patients with advanced or recurrent
non-squamous non-small cell lung cancer (NSCLC):
BO17704 (C Manegold; Abstract LBA7514)
Time: 14:45-15:00
Time: 14:00-18:00
Venue: S Hall A2
Breast cancer – local-regional and adjuvant therapy
X
B
A
A
14
Inflammatory and locally advanced breast cancer respond
similar to operable breast cancer to neoadjuvant
chemotherapy: Results from 278 patients with cT4a-d
tumors of the GeparTRIO trial (G Von Minckwitz;
Poster A1, Abstract 542)
Effect of monthly oral ibandronate on anastrozole-induced
bone loss during adjuvant treatment for breast cancer:
One-year results from the ARIBON study (JE Lester;
Poster A12, Abstract 553)
A pilot study of adjuvant bevacizumab after neoadjuvant
chemotherapy for high-risk breast cancer (EL Mayer;
Poster B6, Abstract 561)
Adjuvant (adj) bevacizumab (B) plus dose-dense (dd)
doxorubicin/cyclophosphamide (AC) followed by
nanoparticle albumin-bound paclitaxel (nab-p) in early
stage breast cancer (BC) patients (pts): Cardiac safety
(MN Dickler; Poster B12, Abstract 567)
A Avastin
X
Xeloda
B Bondronat
21/5/07
18:22
Page 15
Saturday
2 June
H
A
H
A correlative study of cardiac biomarkers and left ventricular
ejection fraction (LVEF) from N9831, a phase III
randomized trial of chemotherapy and trastuzumab as
adjuvant therapy for HER2-positive breast cancer
(LA Kutteh; Poster C10, Abstract 579)
Pathologic complete response (pCR) following weekly
(wkly) paclitaxel (cremophor or albumin-bound) and
carboplatin (TC) ± trastuzumab (H), ± bevacizumab (B) in
patients (pts) with doxorubicin/cyclophosphamide-resistant
(AC-Res) and AC-sensitive (AC-S) large and inflammatory
breast cancer (RS Mehta; Poster D8, Abstract 591)
Time: 14:00-18:00
Venue: S Hall A2
Breast cancer - metastatic
H
H
A
H
H
Safety and efficacy of combined trastuzumab and CMF
therapy in women with metastatic breast cancer: EORTC
protocol 10995 (Z Neskovic-Konstantinovic; Poster G2,
Abstract 1040)
A phase I study of trastuzumab-MCC-DM1 (T-DM1),
a first-in-class HER2 antibody-drug conjugate (ADC),
in patients (pts) with HER2+ metastatic breast cancer (BC)
(M Beeram; Poster G4, Abstract 1042)
Preclinical testing of a novel regimen of capecitabine (C)
in combination with bevacizumab (B) and trastuzumab (T)
in a breast cancer xenograft model (TA Traina; Poster G11,
Abstract 1049)
Efficacy of oral vinorelbine (NVBo), capecitabine (X)
and trastuzumab (H) triple combination (NVBoXH) in
HER2-positive metastatic breast cancer (MBC): First results
of an international phase II trial (A Chan; Poster G14,
Abstract 1052)
H Herceptin
A Avastin
15
21/5/07
18:22
Page 16
Saturday
2 June
X
H
X
A
H
B
H
H
X
H
X
16
Phase II trial of nab-paclitaxel (nanoparticle albuminbound paclitaxel (ABX)) + capecitabine (XEL) in firstline treatment of metastatic breast cancer (MBC)
(SG Bradley; Poster H1, Abstract 1053)
Trastuzumab (T) plus capecitabine (C) in heavily
pretreated patients (pts) with advanced breast cancer
(ABC) (R Bartsch; Poster H3, Abstract 1055)
Chemoprotection by VEGF: Rationale for combination
nab-paclitaxel and bevacizumab (V Trieu; Poster H12,
Abstract 1064)
Activity of trastuzumab (t) beyond disease progression
in HER2 over-expressing metastatic breast cancer (MBC)
(G Metro; Poster H14, Abstract 1066)
Clodronate compared to ibandronate breast cancer bone
metastases patient preference study (S Jagdev; Poster J2,
Abstract 1068)
Inter- and intra-country variations in the use of
trastuzumab in Norway, Spain and Sweden (N Wilking;
Poster J3, Abstract 1069)
Cost-effectiveness of HER2 testing and trastuzumab therapy
for metastatic breast cancer (MBC) patients in Sweden
(M Lidgren; Poster L8; Abstract 1088)
Capecitabine (X) monotherapy as first-line chemotherapy
(CT) for metastatic breast cancer (MBC): High efficacy
regardless of prior therapy (L Mauriac; Poster M1,
Abstract 1092)
Efficacy and safety of trastuzumab plus vinorelbine as
second-line treatment for women with HER2-positive
metastatic breast cancer beyond disease progression
(T Bachelot; Poster M3, Abstract 1094)
Administration of further chemotherapy (CT) after
capecitabine as first-line chemotherapy (CT) for metastatic
breast cancer (MBC) (M Debled; Poster M4, Abstract 1095)
X
Xeloda
H Herceptin
A Avastin
B Bondronat
21/5/07
18:22
Page 17
Saturday
2 June
B
X
A
A
B
Efficacy of i.v. and oral ibandronate in bone metastases
breast cancer patients and some clinical aspects of
bisphosphonates studies: Clinical experience of one trial
center (M Lichinitser; Poster M5, Abstract 1096)
A retrospective review of breast cancer patients with central
nervous system metastasis treated with capecitabine
(M Kurt; Poster M7, Abstract 1098)
Bevacizumab and albumin-bound paclitaxel treatment
in metastatic breast cancer (JS Link; Poster M10,
Abstract 1101)
Randomized phase II trial of three dosing schedules of
nanoparticle albumin-bound paclitaxel with bevacizumab
as first-line therapy for HER2-negative metastatic breast
cancer: An initial interim safety report (AK Conlin;
Poster N2, Abstract 1104)
Renal safety of intravenous ibandronate 6mg infused over
15 or 60 minutes in patients with breast cancer and bone
metastases: A randomized, open-label study (R von Moos;
Poster P1, Abstract 1114)
POSTER DICUSSION SESSION
Time: 14:00-18:00 [discussion 17:00-18:00]
Gastrointestinal (colorectal) cancer
A
A
Bevacizumab (Bev) in combination with XELOX or
FOLFOX4: Updated efficacy results from XELOX-1/
NO16966, a randomized phase III trial in first-line metastatic
colorectal cancer (L Saltz; Poster 15, Abstract 4028)
Comparable safety and response rate with bevacizumab in
combination with capecitabine/oxaliplatin (CapOx/Bev)
versus capecitabine/irinotecan (CapIri/Bev) in advanced CRC
(mCRC): A randomized phase II study of the AIO GI tumor
study group (WH Schmiegel; Poster 21, Abstract 4034)
B Bondronat
X
Xeloda
A Avastin
17
21/5/07
18:22
Page 18
Saturday
2 June
A
Association between exposure to bevacizumab (BV) beyond
first progression (BBP) and overall survival (OS) in patients
(pts) with metastatic colorectal cancer (mCRC): Results
from a large observational study (BRiTE) (A Grothey;
Poster 23, Abstract 4036)
Time: 15:00-18:15
Venue: E Hall D2
Head and neck cancer
T
Final results of a phase II study of erlotinib, docetaxel and
cisplatin in patients with recurrent/metastatic head and neck
cancer (ES Kim; Abstract 6013)
Time: 17:30-17:45
CLINICAL SCIENCE SYMPOSIUM
Time: 16:30-18:00
Venue: N Hall B1
Targeting breast cancer with monoclonal antibodies
and small molecules: beyond HER2
H
Objective response rate in a phase II multicenter trial of
pertuzumab (P), a HER2 dimerization inhibiting
monoclonal antibody, in combination with trastuzumab (T)
in patients (pts) with HER2-positive metastatic breast cancer
(MBC) which has progressed during treatment with T
(J Baselga; Abstract 1004)
Time: 17:30-17:45
18
A Avastin
T
Tarceva
H Herceptin
21/5/07
18:22
Page 19
Sunday
3 June
Time: 08:00-12:00
Venue: S Hall A2
Developmental therapeutics: immunotherapy
M
Lumiliximab (anti-CD23 antibody) mediates apoptosis and
antitumor activity in chronic lymphocytic leukemia (CLL)
cells and CD23+ lymphoma cell lines (N Pathan; Poster E5,
Abstract 3039)
Time: 08:00-12:00
Venue: S Hall A2
Developmental therapeutics: molecular therapeutics
T
A phase I dose escalation pharmacokinetic (PK) and
pharmacodynamic (PD) study of weekly and twice weekly
erlotinib in advanced stage solid malignancies (SK Chia;
Poster M2, Abstract 3594)
Time: 08:00-12:00
Venue: S Hall A2
Lung cancer
T
T
T
Phase II study of erlotinib in chemo-naive women with
advanced pulmonary adenocarcinoma (D Jackman;
Poster P5, Abstract 7591)
Skin rash as surrogate marker of efficacy in patients with
non-small cell lung cancer treated with erlotinib (M Cobo;
Poster Q5, Abstract 7602)
Correlation of the EGFR gene mutation, gene amplification
and protein expression in non-small cell lung cancer with
clinical outcomes of erlotinib monotherapy: An exploratory
analysis of biomarkers by the Korean Cancer Study Group
(M-J Ahn; Poster Q11, Abstract 7608)
M MabThera
T
Tarceva
19
21/5/07
18:22
Page 20
Sunday
3 June
T
T
T
T
T
T
A phase II study of erlotinib (E) and bevacizumab (B)
in patients (pts) with previously untreated stage IIIB/IV
non-small cell lung cancer (NSCLC) (HJ Groen; Poster S6,
Abstract 7625)
Erlotinib for first line treatment in unselected patients (p)
with advanced or metastatic non-small cell lung carcinoma
(NSCLC) (U Jimenez; Poster T9, Abstract 7639)
Erlotinib in non-small cell lung cancer (NSCLC): Interim
safety analysis of the TRUST study (U Gatzemeier;
Poster U4, Abstract 7645)
Cost-effectiveness of erlotinib vs. docetaxel or pemetrexed
in the treatment of refractory non-small cell lung cancer
(NSCLC) (J Carlson; Poster X1, Abstract 7664)
Biomarker analysis from TRUST, a trial of erlotinib in nonsmall cell lung cancer (NSCLC) (C-P Schneider; Poster Y3,
Abstract 7674)
Randomized phase II study of erlotinib alone and in
combination with bortezomib in previously treated
advanced non-small cell lung cancer (NSCLC) (TJ Lynch;
Poster Z1, Abstract 7680)
Time: 09:00-12:00
Venue: N Hall B1
Breast cancer – metastatic
X
Phase III trial of ixabepilone plus capecitabine compared to
capecitabine alone in patients with metastatic breast cancer
(MBC) previously treated or resistant to an anthracycline
and resistant to taxanes (LT Vahdat; Abstract 1006)
Time: 09:15-09:30
20
T
Tarceva
X
Xeloda
21/5/07
18:22
Page 21
Sunday
3 June
H
BCIRG 007: First overall survival analysis of randomized
phase III trial of trastuzumab plus docetaxel with or without
carboplatin as first line therapy in HER2 amplified
metastatic breast cancer (MBC) (MD Pegram;
Abstract LBA1008)
Time: 09:45-10:00
A
X
Safety and efficacy of capecitabine (C) plus bevacizumab (B)
as first-line in metastatic breast cancer (G Sledge;
Abstract 1013)
Time: 11:30-11:45
Time: 09:30-12:30
Venue: E354b
Lymphoma
M
Revalidation of FLIPI in patients with follicular lymphoma
(FL) registered in the F2 study and treated upfront with
immunochemotherapy (M Federico; Abstract 8008)
Time: 09:30-09:45
M
Long-term results of the GELA study comparing R-CHOP
and CHOP chemotherapy in older patients with diffuse
large B-cell lymphoma show good survival in poor-risk
patients (B Coiffier; Abstract 8009)
Time: 09:45-10:00
M
Rituximab compared to observation after high-dose
consolidative first-line chemotherapy (HDC) with
autologous stem cell transplantation in poor-risk diffuse
large B-cell lymphoma: Updated results of the LNH98-B3
GELA study (C Haioun; Abstract 8012)
Time: 10:45-11:00
H Herceptin
A Avastin
X
Xeloda
M MabThera
21
21/5/07
18:22
Page 22
Sunday
3 June
Time: 13:00-16:00
Venue: E354b
Myeloma
M
Long-term responses to thalidomide and rituximab in
Waldenstrom's macroglobulinemia (JD Soumerai;
Abstract 8017)
Time: 13:00-13:15
Time: 14:00-18:00
Venue: S Hall A2
Pediatric cancer
T
ITCC phase I study of erlotinib as single agent in children
with refractory and relapsed malignant brain tumors and in
combination with irradiation in newly diagnosed brain stem
glioma (B Geoerger; Poster Z8, Abstract 9556)
POSTER DISCUSSION SESSION
Time: 14:00-18:00 [discussion 17:00-18:00]
H
Neoadjuvant trastuzumab in locally advanced breast cancer
(NOAH): Antitumour and safety analysis (L Gianni;
Time: 14:00-18:00 [discussion 17:00-18:00]
Venue: S102a [S100b]
Developmental therapeutics: immunotherapy
H
22
A phase II trial of trastuzumab and low dose interleukin-2 in
patients with metastatic breast cancer who have previously
failed trastuzumab (A Mani; Poster 19, Abstract 3028)
M MabThera
T
Tarceva
H Herceptin
21/5/07
18:22
Page 23
Sunday
3 June
CLINICAL SCIENCE SYMPOSIUM
Time: 16:30-18:00
Venue: E354b
Improving survival in follicular lymphoma:
integrating new therapy
M
Prospective, multicenter, randomized GITMO-IIL trial
comparing intensive (R-HDS) to conventional
chemoimmunotherapy (CHOP-R) in high-risk follicular
lymphoma (FL) at diagnosis (M Ladetto; Abstract 8006)
Time: 17:30-17:45
M MabThera
23
21/5/07
18:22
Page 24
Monday
4 June
Time: 08:00-12:00
Venue: S Hall A2
Gastrointestinal (colorectal) cancer
A
A
A
A
A
A
A
24
Phase I/II study of neoadjuvant bevacizumab with radiation
therapy and 5-fluorouracil in patients with rectal cancer:
initial results (C Willett; Poster A3, Abstract 4041)
Effectiveness of neoadjuvant chemotherapy including
bevacizumab in patients with resectable colorectal cancer
liver metastases (B Gruenberger; Poster D1, Abstract 4060)
Bevacizumab plus XELOX as neoadjuvant therapy for
patients with potentially curable metastatic colorectal cancer
(T Gruenberger; Poster D5, Abstract 4064)
Phase IV study of first-line bevacizumab plus irinotecan and
infusional 5-FU/LV in patients with metastatic colorectal
cancer: AVIRI (AF Sobrero; Poster E2, Abstract 4068)
Preliminary efficacy of bevacizumab with first-line
FOLFOX, XELOX, FOLFIRI and monotherapy for mCRC:
First BEATrial (A Kretzschmar; Poster E6, Abstract 4072)
Magnitude of progression-free survival (PFS) improvement
and treatment (Tx) duration in metastatic colorectal cancer
(mCRC) for bevacizumab (BV) in combination with
oxaliplatin-containing regimens: An analysis of two phase III
studies (BJ Giantonio; Poster E7, Abstract 4073)
A comparison of medical resource use for 4 chemotherapy
regimens as first-line treatment for metastatic colorectal
cancer (MCRC): XELOX vs. FOLFOX4 ± bevacizumab (A)
(W Scheithauer; Poster J4, Abstract 4098)
A Avastin
21/5/07
18:22
Page 25
Monday
4 June
Time: 08:00-12:00
Venue: S Hall A2
Gastrointestinal (noncolorectal) cancer
T
A phase I study of erlotinib, bevacizumab and gemcitabine
in patients with advanced pancreatic cancer
(C Gomez-Martin; Poster BB2, Abstract 4611)
Time: 08:00-12:00 [discussion 11:00-12:00]
Venue: E451a [E354b]
Leukemia, myelodysplasia and transplantation
M
Beta-2 microglobulin (B2M) is an independent prognostic
factor for clinical outcomes in patients with CLL treated
with frontline fludarabine, cyclophosphamide, and
rituximab (FCR) regardless of age, creatinine clearance
(CrCl) (AM Tsimberidou; Poster 22, Abstract 7034)
Time: 09:00-12:00
Venue: E Hall D1
H
Updated results of the combined analysis of NCCTG N9831
and NSABP B-31 adjuvant chemotherapy with/without
trastuzumab in patients with HER2-positive breast cancer
(E Perez; Abstract 512)
Time: 09:00-09:15
H
Five year update of cardiac dysfunction on NSABP B-31,
a randomized trial of sequential doxorubicin/
cyclophosphamide (AC) paclitaxel (T) vs. AC T with
trastuzumab (H) (P Rastogi; Abstract LBA513)
Time: 09:15-09:30
T
Tarceva
M MabThera
H Herceptin
25
21/5/07
18:22
Page 26
Monday
4 June
SPECIAL SESSION
Time: 13:00-16:00
Venue: N Hall B1
Monday plenary session
A
A randomized, controlled, double-blind phase III study
(AVOREN) of bevacizumab/interferon-␣2a vs
placebo/interferon-␣2a as first-line therapy in metastatic
renal cell carcinoma (B Escudier; Abstract 3)
Time: 14:30-14:45
Time: 14:00-18:00 [discussion 17:00-18:00]
Venue: E451a [E354b]
Lymphoma and plasma cell disorders
M
M
M
M
26
A phase I/II study of lenalidomide (Len) in combination
with rituximab (R) in relapsed/refractory mantle cell
lymphoma (MCL) with early evidence of efficacy
(M Wang; Poster 5, Abstact 8030)
Bendamustine and rituximab (BR) are effective in the
treatment of relapsed or refractory indolent and mantle-cell
lymphomas: Long-term follow-up of a phase II study
(MJ Rummel; Poster 9, Abstract 8034)
Efficacy and toxicity of dose-adjusted EPOCH-rituximab
in adults with newly diagnosed Burkitt lymphoma
(K Dunleavy; Poster 10, Abstract 8035)
R-Dhaox, high dose chemotherapy (HDC) and rituximab
maintenance as salvage treatment in relapsed/refractory
(R/R) follicular (F) and mantle cells (MC) lymphomas
(NHL) (M Rupolo; Poster 11, Abstract 8036)
A Avastin
M MabThera
21/5/07
18:22
Page 27
Monday
4 June
M
M
M
Incidence and risk factors for central nervous system relapse
in patients with diffuse large B-cell lymphoma: The impact
of the addition of rituximab to CHOP chemotherapy
(D Villa; Poster 12, Abstract 8037)
Effect of addition of rituximab to CHOP on survival of
patients in both the GCB and non-GCB subgroups of diffuse
large B-cell lymphoma (K Fu; Poster 15, Abstract 8040)
Rituximab induces long-term remissions in patients with
HIV-associated multicentric Castleman's disease (M Bower;
M MabThera
27
21/5/07
18:22
Page 28
Tuesday
5 June
Time: 08:00-12:00 [discussion 11:00-12:00]
Venue: E451a [E354a]
Lung cancer II
T
28
Updated molecular analyses of exons 19 and 21 of the
epidermal growth factor receptor (EGFR) gene and codons
12 and 13 of the KRAS gene in non-small cell lung cancer
(NSCLC) patients treated with erlotinib in National Cancer
Institute of Cancer (FA Shepherd; Poster 20, Abstract 7571)
T
Tarceva
21/5/07
18:22
Page 29
29
21/5/07
18:22
Page 30
Hotels
Chicago Marriott Downtown
Magnificent Mile
540 North Michigan Avenue,
Chicago, IL 60611
Tel: 312 836 0100; Fax: 312 836 6139
www.marriott.com
Breakfast: Ventoso, 06:00-11:00
Hyatt Regency Chicago
151 East Wacker Drive,
Chicago, IL 60601
Tel: 312 565 1234; Fax: 312 239 4414
www.chicagoregency.hyatt.com
Breakfast: The Bistro at 151,
East Tower, Green Level, 06:00-11:00
Four Points by Sheraton
630 North Rush Street,
Chicago, IL 60611
Tel: 312 981 6600; Fax: 312 981 6622
www.fourpointschicago.com
Breakfast: Chicago's Room,
4th floor,
Mon-Fri 06:30-10:00;
Sat/Sun 07:00-10:30
Hyatt Regency McCormick Place
2233 South Martin Luther King
Drive, Chicago, IL 60616
Tel: 312 567 1234; Fax: 312 528 4000
www.mccormickplace.hyatt.com
Breakfast: Shor, Grand Concourse,
06:30-11:00
Four Seasons Hotel Chicago
120 East Delaware Place,
Chicago, IL 60611
Tel: 312 280 8800; Fax: 312 280 1748
www.fourseasons.com
Breakfast: Seasons, 06:30-10:00
Hilton Chicago
720 South Michigan Avenue,
Chicago, IL 60605
Tel: 312 922 4400; Fax: 312 922 5240
www1.hilton.com
Breakfast: The Pavilion,
Mon-Fri 05:30-11:00;
Sat 05:30-12:00; Sun 05:30-14:00
Hotel Orrington
1710 Orrington Avenue,
Evanston, IL 60201
Tel: 847 866 8700; Fax: 847 866 8724
www.hotelorrington.com
Breakfast: The Globe Café,
1st floor, 06:00-09:00
House of Blues Hotel
333 North Dearborn Street,
Chicago, IL 60610
Tel: 312 245 0333; Fax: 312 923 2458
www.houseofblueshotel.com
Breakfast: Bin36,
Mon-Fri 06:30-10:00;
Sat/Sun 07:00-12:00
30
Palmer House Hilton
17 East Monroe Street,
Chicago, IL 60603
Tel: 312 726 7500; Fax: 312 917 1707
www1.hilton.com
Breakfast: The Big Downtown,
lower level, 06:30-10:00
Ritz-Carlton Chicago
160 East Pearson Street,
Chicago, IL 60611
Tel: 312 266 1000; Fax: 312 266 1194
www.fourseasons.com
Breakfast: The Café, 06:30-11:00
Whitehall Hotel
105 East Delaware Place,
Chicago, IL 60611
Tel: 312 944 6300; Fax: 312 944 8552
www.thewhitehallhotel.com
Breakfast: Fornetto Mei,
1st floor, 07:00-11:00
21/5/07
18:22
Page 31
Map
Golf
Evanston Hotel Orrington
Morton
Grove
Edens Expy W
Oakton
Skokie
Niles
Edens Expy W
Lincolnwood
Kennedy E
xp
yW
Rogers
Park
Uptown
Summerdale
Ke
nn
Lincoln
Park
ed
yE
xp
yW
N State st
Chicago
Downtown
Lincoln
Park
Elmwood
Park
Near
North Side
W Division St
Oak
Park
Chicago
Eisenhower Expy W
Four Seasons
Eisenhower Expy W
Whitehall
W Chicago Ave
Ritz Carlton
Four Points Sheraton
W Ontario
Marriot
W Ohio
Navy Pier
House of Blues
Hyatt Regency
E Wacker D
r
W Wacker Dr
W Randolph St
Columbus Dr
Palmer House
W Jackson Blvd
Lake
Michigan
Congress Parkway
E Balbo Dr
Hilton
W Roosevelt Rd
rive
hore D
Lake S
S Michigan Ave
S State st
Hyatt Regency McCormick
S Martin
W Cermak Rd
McCormick Place
ng
Ki
er
Luth
Dr
31
Notes
32
21/5/07
18:22
Page 32
21/5/07
18:22
Page 33
Notes
33
Notes
34
21/5/07
18:22
Page 34
21/5/07
18:22
Page 35
F. Hoffmann-La Roche Ltd
CH-4070 Basel
Switzerland
21/5/07
18:22
Page 36

McCormick Place Chicago, IL, USA

Transcription

Similar documents

Studien Medizinische Klinik II, Homepage